Home
HelpTest Code LAB0202598 Catecholamine Fractionation, Free, Plasma
Additional Codes
| Mayo Test ID |
|---|
| CATP |
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Useful For
Diagnosing pheochromocytoma and paraganglioma, as an auxiliary test to fractionated plasma and urine metanephrine measurements
Diagnosis follow-up of patients with neuroblastoma and related tumors, as an auxiliary test to urine vanillylmandelic acid and homovanillic acid measurements
Evaluation of patients with autonomic dysfunction or failure or autonomic neuropathy
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
Catecholamine Fract, Free, PSpecimen Type
Plasma EDTA MetaOrdering Guidance
To preserve the quality of the specimen, this test should be its own collection. Sharing the specimen could introduce unforeseen analysis interferences.
This test is not the first-tier test for pheochromocytoma, as plasma catecholamine levels may not be continuously elevated. For the recommended first-tier laboratory test for pheochromocytoma, order either:
-PMET / Metanephrines, Fractionated, Free, Plasma
-METAF / Metanephrines, Fractionated, 24 Hour, Urine
Do not perform this test on patients withdrawing from legal or illegal drugs known to cause rebound plasma catecholamine release during withdrawal (see Cautions for details).
Specimen Required
Patient Preparation:
1. Discontinue drugs that release epinephrine, norepinephrine, or dopamine, or hinder their metabolism, for at least one week before obtaining the specimen (see Cautions for details). If this is not possible for medical reasons, contact the laboratory and discuss whether a shorter drug withdrawal period may be possible in a particular case.
2. Unless the purpose of the measurement is drug monitoring, discontinue any epinephrine, norepinephrine, or dopamine injections or infusions for at least 12 hours before specimen collection.
3. The patient must refrain from eating, using tobacco, and drinking caffeinated beverages for at least 4 hours before the specimen is collected.
Supplies: Catecholamine Tubes-EDTA (T066) (tubes contain sodium metabisulfite, may come as 10-mL or 6-mL tubes, and have a 6-month expiration time)
Collection Container/Tube:
Preferred: 10-mL Catecholamine tubes containing EDTA-sodium metabisulfite solution
Acceptable: 6-mL Catecholamine tubes containing EDTA-sodium metabisulfite solution
Submission Container/Tube: Plastic vial
Specimen Volume: 3 mL
Collection Instructions:
Note: If the collection instructions are not followed, falsely elevated test results are highly likely.
1. Drawing from an indwelling intravenous (IV) line/catheter/butterfly is required.
2. Calm the patient by giving complete instructions and reassurance regarding the procedure.
3. Insert an indwelling IV catheter. Flush with 3 mL of sodium chloride (NaCl) using positive pressure.
4. Have the patient rest for 30 minutes in the supine position in a quiet room.
5. At the end of the 30 minutes, withdraw and discard a minimum of 3 mL of blood to remove the saline out of the catheter.
6. If provocative sampling (eg, standing specimen) is required, perform provocative maneuver immediately after obtaining supine specimen. Obtain standing specimen immediately.
7. For each specimen, draw 10 mL of blood into the chilled 10 mL catecholamine tube containing EDTA-sodium metabisulfite solution. A 6 mL pink top EDTA-metabisulfite tube is an acceptable substitute.
8. Specimens must remain at refrigerated temperature during processing and transport.
9. Separate plasma in a refrigerated centrifuge within 30 minutes of collection.
10. Freeze specimen immediately.
Freeze plasma within 1 hour of collection and submit frozen.
Specimen Minimum Volume
2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma EDTA Meta | Frozen | 28 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | OK |
Reference Values
NOREPINEPHRINE
Supine: 70-750 pg/mL
Standing: 200-1700 pg/mL
EPINEPHRINE
Supine: <111 pg/mL
Standing: <141 pg/mL
DOPAMINE
<30 pg/mL (no postural change)
For International System of Units (SI) conversion for Reference Values, see www.mayocliniclabs.com/order-tests/si-unit-conversion.html.
Interpretation
Diagnosis of Pheochromocytoma:
This test should not be used as the first-line test for pheochromocytoma, as plasma catecholamine levels may not be continuously elevated but only secreted during a "spell." By contrast, production of metanephrines (catecholamine metabolites) appears to be increased continuously.
The recommended first-line laboratory tests for pheochromocytoma are:
-PMET / Metanephrines, Fractionated, Free, Plasma: the most sensitive assay
-METAF / Metanephrines, Fractionated, 24 Hour, Urine: highly specific and almost as sensitive as PMET
However, plasma catecholamine measurements can be useful in patients whose plasma metanephrine or urine metanephrine measurements do not completely exclude the diagnosis. In such cases, plasma catecholamine specimens, if collected during a "spell," have a 90% to 95% diagnostic sensitivity when cutoffs of 750 pg/mL for norepinephrine and 110 pg/mL for epinephrine are employed. A lower value during a "spell," particularly when plasma or urinary metanephrine measurements were also normal, essentially rules out pheochromocytoma. Unfortunately, the specificity of these high-sensitivity cutoff levels is not adequate for separating tumor patients from other patients with similar symptoms. When more specific (95%) decision levels of 2000 pg/mL for norepinephrine or 200 pg/mL for epinephrine are used, the assay's sensitivity falls to about 85%.
Diagnosis of Neuroblastoma:
Vanillylmandelic acid, homovanillic acid, and, sometimes, urine catecholamine measurements using random urine or 24-hour urine collections are the mainstay of biochemical diagnosis and follow-up of neuroblastoma. Plasma catecholamine levels can aid diagnosis in some cases, but diagnostic decision levels are not well established. The most useful finding is disproportional elevations in 1 of the 3 catecholamines, particularly dopamine, which may be observed in these tumors.
Diagnosis of Autonomic Dysfunction or Failure and Autonomic Neuropathy:
Depending on the underlying cause and pathology, autonomic dysfunction or failure and autonomic neuropathies are associated with subnormal resting norepinephrine levels or an absent rise of catecholamine levels in response to physiological release stimuli (eg, change in posture from supine to standing, cold exposure, exercise, stress), or both. In addition, there may be significant abnormalities in the ratios of the plasma values of the catecholamines to each other (normal: norepinephrine>epinephrine>dopamine). This is observed most strikingly in the inherited dysautonomic disorder dopamine-beta-hydroxylase deficiency, which results in markedly elevated plasma dopamine levels and a virtually total absence of plasma epinephrine and norepinephrine.
Day(s) Performed
Monday through Friday
Report Available
2 to 6 daysSpecimen Retention Time
14 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82384
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CATP | Catecholamine Fract, Free, P | 34551-2 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 2846 | Norepinephrine | 2666-6 |
| 2901 | Epinephrine | 2230-1 |
| 2906 | Dopamine | 2216-0 |
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.